Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze DMAC stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate DMAC investment potential.

What is DMAC stock price today?

Get real-time DMAC stock price, historical data, and price charts on Financhill. Track DMAC performance with our advanced analysis tools.

Is DMAC a good investment?

Evaluate DMAC investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy DMAC stock?

To buy DMAC stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of DMAC?

View detailed market capitalization data and company valuation metrics for DMAC on our comprehensive analysis page.

What is the P/E ratio of DMAC?

Use our fundamental analysis tools to view DMAC P/E ratio and compare valuation metrics with industry peers.

What are DMAC earnings?

View DMAC earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

DiaMedica Therapeutics, Inc. 10K Form

Buy

DMAC
DiaMedica Therapeutics, Inc.

Last Price:

$8.80

Seasonality Move:

25.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-11	10Q	DMAC/DiaMedica Therapeutics, Inc. Quarterly
2020-05-13	10Q	DMAC/DiaMedica Therapeutics, Inc. Quarterly
2020-03-23	10K	DMAC/DiaMedica Therapeutics, Inc. Annual
2019-11-13	10Q	DMAC/DiaMedica Therapeutics, Inc. Quarterly
2019-08-13	10Q	DMAC/DiaMedica Therapeutics, Inc. Quarterly
2019-05-13	10Q	DMAC/DiaMedica Therapeutics, Inc. Quarterly

Receive DMAC News And Ratings

See the #1 stock for the next 7 days that we like better than DMAC

DMAC Financial Statistics

Sales & Book Value

Annual Sales:	$0
Cash Flow:	$-6.6M
Price / Cash Flow:	0
Annual Sales:	$0.99
Price / Book:	8.86

Profitability

EPS (TTM):	-0.71730
Net Income (TTM):	$-31.9M
Gross Margin:	$-39K
Return on Equity:	-79.25%
Return on Assets:	-70.57%

DiaMedica Therapeutics, Inc. Earnings Forecast

Key DiaMedica Therapeutics, Inc. Financial Ratios

Per Share Earnings over the last 21 years have been positive in 9 years.

DiaMedica Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	DMAC
CUSIP:	25253X
Website:	diamedica.com

Debt

Debt-to-Equity Ratio:	0.01
Current Ratio:	10.67
Quick Ratio:	10.5

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

DMAC Technical Analysis vs Fundamental Analysis

Buy

DiaMedica Therapeutics, Inc. (DMAC) is a Buy

Is DiaMedica Therapeutics, Inc. a Buy or a Sell?

DiaMedica Therapeutics, Inc. stock is rated a Buy

The current DiaMedica Therapeutics, Inc. [DMAC] share price is $8.78. The Score for DMAC is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.